Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford Academic Health Partners (OAHP) is delighted to have been designated as an NIHR/NHSE/I Academic Health Science Centre following the recent competitive designation process. The designation comes into effect from 1 April 2020 and is for an initial period of five years.

The OAHP includes Oxford Health NHS FT, Oxford University Hospitals NHS FT, Oxford Brookes University and the University of Oxford, who have been working closely together for the last six years in key areas including clinical research, multi-disciplinary education and healthcare innovations supporting the local needs and identified priorities.

OAHP’s vision is to respond to major challenges facing healthcare such as healthy ageing, multimorbidity and mental health, antimicrobial resistance and the best use of digital tools to improve care and patient self-management.

The OAHP is currently focusing their staff, facilities and expertise to overcome the COVID-19 pandemic, and using the close collaborations between the partners to make rapid progress in areas such as clinical trials of new treatments for COVID-19 patients in the NHS.  Daily examples of the excellent work and progress in this area can be seen across the media, with partners joining colleagues across the UK and beyond.

Professor Sir John Bell, Chairman of the OAHP said: “the strength of the partners and our plans are clear in all aspects of our work and our commitment to improve every aspect of patient care, research, innovation, education and training in ways that will benefit the changing NHS and its patients as a whole.”

Professor Keith Channon, Director of the OAHP, said: “This success reflects very strong working relationships between the Partners and the intention is now to deliver even more for current challenges, ongoing patient care, and in teaching, education and training and research and innovation.”

“Each partner has its own special set of skills and areas of expertise and together the OAHP can bring these together and work not only across Oxfordshire but regionally and nationally.”

Read more on the Oxford Academic Health Partners website

Similar stories

General anaesthesia should be available for dying patients - medical and ethical experts

General Research

General anaesthesia should be more widely available for patients at the end of their lives, according to Oxford experts in ethics and anaesthesia, according to a paper published by Anaesthesia (a journal of the Association of Anaesthetists).

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.